MediaNewsPublicationsVideosAwareness CampaignsNewsPrintTweet02/05/2021Anna Bigas, new Deputy Director of Preclinical Research at the Josep Carreras Leukemia Research InstituteMore02/05/2021Anna Bigas, new Deputy Director of Preclinical Research at the Josep Carreras Leukemia Research InstituteMore01/18/2021New epigenetic targets identified for the potential treatment of multiple myelomaMore12/31/2020Discovered the explanation of the patients with “lazarus-like” cancerMore12/29/2020New advances in acute lymphoblastic leukaemia in adultsMore12/29/2020Researchers from the Josep Carreras Institute received one of the five grants awarded worldwide by the Facebook founder’s Foundation to study COVID-19More12/09/2020A new study from Josep Carreras Institute reveals a new prognostic marker in a specific subtype of acute lymphoblastic leukemia (ALL) with adverse outcome in infantsMore11/25/2020Dr. Marcus Buschbeck leads the European Network INTERCEPT-MDS focusing on the shared training and research in Myeloid DiseasesMore09/15/2020The Josep Carreras Leukaemia Research Institute identifies a marker of poor evolution in Hodgkin's lymphomaMore08/12/2020A cancer mystery of more than forty years ago is solved thanks to EpigeneticsMoreFirstPrevious12345678910NextLastWebpage updated 10/16/2019 13:23:15
02/05/2021Anna Bigas, new Deputy Director of Preclinical Research at the Josep Carreras Leukemia Research InstituteMore
02/05/2021Anna Bigas, new Deputy Director of Preclinical Research at the Josep Carreras Leukemia Research InstituteMore
12/29/2020Researchers from the Josep Carreras Institute received one of the five grants awarded worldwide by the Facebook founder’s Foundation to study COVID-19More
12/09/2020A new study from Josep Carreras Institute reveals a new prognostic marker in a specific subtype of acute lymphoblastic leukemia (ALL) with adverse outcome in infantsMore
11/25/2020Dr. Marcus Buschbeck leads the European Network INTERCEPT-MDS focusing on the shared training and research in Myeloid DiseasesMore
09/15/2020The Josep Carreras Leukaemia Research Institute identifies a marker of poor evolution in Hodgkin's lymphomaMore
José Carreras Leukaemia Foundation